142 related articles for article (PubMed ID: 6421083)
1. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women.
Mattsson LA; Cullberg G
Acta Obstet Gynecol Scand; 1983; 62(5):397-401. PubMed ID: 6421083
[TBL] [Abstract][Full Text] [Related]
2. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women.
Mattsson LA; Cullberg G
Acta Obstet Gynecol Scand; 1983; 62(5):393-6. PubMed ID: 6421082
[TBL] [Abstract][Full Text] [Related]
3. Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy.
Trevoux R; van der Velden WH; Popović D
Reproduccion; 1982; 6(2):101-6. PubMed ID: 7141096
[TBL] [Abstract][Full Text] [Related]
4. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects.
Kicovic PM; Cortes-Prieto J; Milojević S; Haspels AA; Aljinovic A
Maturitas; 1980 Dec; 2(4):275-82. PubMed ID: 6785553
[TBL] [Abstract][Full Text] [Related]
5. A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy.
Luisi M; Franchi F; Kicovic PM
Maturitas; 1980 Dec; 2(4):311-9. PubMed ID: 6262604
[TBL] [Abstract][Full Text] [Related]
6. Endocrinological and clinical investigations in post-menopausal women following administration of vaginal cream containing oestriol.
Haspels AA; Luisi M; Kicovic PM
Maturitas; 1981 Dec; 3(3-4):321-7. PubMed ID: 6801440
[TBL] [Abstract][Full Text] [Related]
7. Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels.
Schiff I; Tulchinsky D; Ryan KJ; Kadner S; Levitz M
Am J Obstet Gynecol; 1980 Dec; 138(8):1137-41. PubMed ID: 6778214
[TBL] [Abstract][Full Text] [Related]
8. [Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience].
Oliva FA; Saltarelli E; D'Antonio GD; Mazzatenta E
Minerva Ginecol; 1991 Dec; 43(12):605-7. PubMed ID: 1819780
[TBL] [Abstract][Full Text] [Related]
9. Estriol in the management of the menopause.
Tzingounis VA; Aksu MF; Greenblatt RB
JAMA; 1978 Apr; 239(16):1638-41. PubMed ID: 633576
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.
Sánchez-Rovira P; Hirschberg AL; Gil-Gil M; Bermejo-De Las Heras B; Nieto-Magro C
Oncologist; 2020 Dec; 25(12):e1846-1854. PubMed ID: 32459035
[TBL] [Abstract][Full Text] [Related]
11. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Stute P
Arch Gynecol Obstet; 2013 Dec; 288(6):1199-201. PubMed ID: 24178484
[TBL] [Abstract][Full Text] [Related]
12. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy.
Barentsen R; van de Weijer PH; Schram JH
Eur J Obstet Gynecol Reprod Biol; 1997 Jan; 71(1):73-80. PubMed ID: 9031963
[TBL] [Abstract][Full Text] [Related]
13. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.
Biglia N; Peano E; Sgandurra P; Moggio G; Panuccio E; Migliardi M; Ravarino N; Ponzone R; Sismondi P
Gynecol Endocrinol; 2010 Jun; 26(6):404-12. PubMed ID: 20196634
[TBL] [Abstract][Full Text] [Related]
14. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women.
Mandel FP; Geola FL; Meldrum DR; Lu JH; Eggena P; Sambhi MP; Hershman JM; Judd HL
J Clin Endocrinol Metab; 1983 Jul; 57(1):133-9. PubMed ID: 6304131
[TBL] [Abstract][Full Text] [Related]
15. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
Voipio SK; Komi J; Kangas L; Halonen K; DeGregorio MW; Erkkola RU
Maturitas; 2002 Nov; 43(3):207-14. PubMed ID: 12443837
[TBL] [Abstract][Full Text] [Related]
16. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
17. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of vaginal atrophy with isoflavone vaginal gel.
Lima SM; Yamada SS; Reis BF; Postigo S; Galvão da Silva MA; Aoki T
Maturitas; 2013 Mar; 74(3):252-8. PubMed ID: 23312487
[TBL] [Abstract][Full Text] [Related]
19. Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
Matarazzo MG; Caruso S; Giunta G; Valenti G; Sarpietro G; Cianci A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():75-79. PubMed ID: 29367168
[TBL] [Abstract][Full Text] [Related]
20. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
Caruso S; Cianci S; Amore FF; Ventura B; Bambili E; Spadola S; Cianci A
Menopause; 2016 Jan; 23(1):47-54. PubMed ID: 26079974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
